Editorial Material
Medicine, General & Internal
Guadalupe Garcia-Tsao
Summary: NASH has become the main cause of cirrhosis and liver transplantation, unlike hepatitis C which is a liver-specific disorder. It is a complex metabolic disorder that requires finding alternative therapies and defining response to treatment, with diagnosis established through liver biopsy samples.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Mimi Zhai, Zhide Liu, Jianhai Long, Qingxiang Zhou, Leping Yang, Qin Zhou, Sushun Liu, Yu Dai
Summary: The global incidence of liver cirrhosis caused by NASH has been increasing each year, with varying trends observed across different regions and sociodemographic indices. The middle-high and middle SDI regions showed the highest increase, while the high SDI region demonstrated a slower growth. Eastern Europe, Andean Latin America, and Central Asia showed a more significant growth trend in ASR.
SCIENTIFIC REPORTS
(2021)
Article
Environmental Sciences
Trang VoPham, Nicole J. Kim, Kristin Berry, Jason A. Mendoza, Joel D. Kaufman, George N. Ioannou
Summary: This study found a positive association between ambient PM2.5 exposure and odds of NAFLD among hospitalized patients using nationwide cross-sectional analysis. The effect of this association varied based on factors such as age, race, diabetes, smoking, and region.
ENVIRONMENTAL RESEARCH
(2022)
Review
Gastroenterology & Hepatology
Margaret L. P. Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren J. H. Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah
Summary: Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease worldwide, with a higher incidence among males. The global prevalence of NAFLD among adults is 32%, and it has been increasing over time. The prevalence varies by world region, with the Americas and South-East Asia having the highest rates. If current trends continue, the prevalence of NAFLD is projected to increase significantly by 2030.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Haoyu Tian, Shuairan Zhang, Ying Liu, Yifan Wu, Dianbao Zhang
Summary: Nonalcoholic fatty liver disease (NAFLD) is a chronic condition associated with metabolic dysfunction and obesity, and has become an epidemic worldwide. There is currently no FDA-approved drug for NAFLD, but fibroblast growth factors (FGFs) have shown promising therapeutic benefits in clinical trials. FGF-based therapies, particularly FGF analogs, have been effective in treating NAFLD by alleviating steatosis, liver inflammation, and fibrosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Javier Ampuero, Rocio Aller, Rocio Gallego-Duran, Javier Crespo, Javier Abad, Agueda Gonzalez-Rodriguez, Judith Gomez-Camarero, Joan Caballeria, Oreste Lo Iacono, Luis Ibanez, Javier Garcia-Samaniego, Rosa Martin-Mateos, Ruben Frances, Conrado Fernandez-Rodriguez, Moises Diago, German Soriano, Raul J. Andrade, Raquel Latorre, Francisco Jorquera, Rosa M. Morillas, Desam Escudero, Pamela Estevez, Manuel Hernandez-Guerra, Salvador Augustin, Maria Jesus Pareja-Megia, Jesus M. Banales, Patricia Aspichueta, Salvador Benlloch, Jose Miguel Rosales, Javier Salmeron, Juan Turnes, Manuel Romero-Gomez
Summary: The study investigated the distribution of NASH and its components across fibrosis stages, revealing a decrease in steatohepatitis prevalence in advanced liver disease. However, most patients still showed inflammatory activity and metabolic disturbances. The risk of cirrhosis progression was similar between NASH and indeterminate NASH patients.
LIVER INTERNATIONAL
(2021)
Article
Cardiac & Cardiovascular Systems
Jianwei Wu, Jiahuan Guo, Anxin Wang, Yijun Zhang, Shouling Wu, Yanfang Liu, Xingquan Zhao
Summary: This study aimed to investigate the association between the severity of nonalcoholic fatty liver disease (NAFLD) steatosis and the risk of future intracerebral hemorrhage (ICH). The results showed that persistent moderate steatosis was significantly associated with an increased risk of future ICH, independent of other conventional risk factors.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
(2022)
Review
Medicine, Research & Experimental
Yifei Chen, Fuji Yang, Ying Chu, Zhihua Yun, Yongmin Yan, Jianhua Jin
Summary: Metabolic diseases, including obesity, diabetes, and nonalcoholic fatty liver disease, are increasing in incidence and prevalence, posing a major health and socioeconomic burden globally. While there is growing understanding of these diseases, effective treatments remain a challenge. Recent research suggests that mitochondrial dysfunction plays a role in the pathogenesis of metabolic diseases, and the use of healthy mitochondria as a therapeutic approach shows promise.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Review
Gastroenterology & Hepatology
Richie Manikat, Mindie H. Nguyen
Summary: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by excess fat accumulation in the liver. It is associated with metabolic syndrome and often presents with comorbidities such as obesity, type 2 diabetes mellitus, and dyslipidemia. NAFLD is also linked to non-liver comorbidities including cardiovascular disease, chronic kidney disease, and sleep apnea. Managing these comorbidities is crucial for improving liver-related and overall health outcomes in patients with NAFLD.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Review
Medicine, Research & Experimental
Jiashu Pan, Wenjun Zhou, Ruohui Xu, Lianjun Xing, Guang Ji, Yanqi Dang
Summary: This study summarizes the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and the urgent need for approved treatment. It highlights the important role of peroxisome proliferator activated receptors (PPARs) in regulating NAFLD and summarizes natural products that target PPARs to treat NAFLD.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Gastroenterology & Hepatology
Soumya Murag, Aijaz Ahmed, Donghee Kim
Summary: The rising prevalence of nonalcoholic fatty liver disease (NAFLD) due to the obesity epidemic and metabolic syndrome has led to increased healthcare costs. Diagnostic challenges include identifying NAFLD patients at higher risk of progressing to end-stage liver disease.
Article
Gastroenterology & Hepatology
Pegah Golabi, Vasily Isakov, Zobair M. Younossi
Summary: The prevalence of NAFLD is increasing worldwide due to obesity and T2DM. It is projected that the proportion of NASH and NAFLD will continue to rise, leading to more advanced stages of liver disease, an increase in hepatocellular cancer cases, and the need for liver transplantation. To address this burden, effective programs to raise awareness and identify at-risk patients must be implemented in accordance with national and regional guidelines. Additionally, the development of new therapeutic regimens for progressive NASH should be pursued.
CLINICS IN LIVER DISEASE
(2023)
Review
Biochemistry & Molecular Biology
Giorgio Bedogni, Francesco Palmese, Francesco Giuseppe Foschi
Summary: The article discusses two controversial issues in fatty liver research: the proposal to replace nonalcoholic fatty liver disease (NAFLD) with metabolically associated fatty liver disease (MAFLD), and the suggestion to extend noninvasive testing for liver fibrosis from secondary care to primary care.
CURRENT OPINION IN LIPIDOLOGY
(2023)
Article
Gastroenterology & Hepatology
Dong Hyun Sinn, Danbee Kang, Sung Chul Choi, Yun Soo Hong, Di Zhao, Eliseo Guallar, Yewan Park, Juhee Cho, Geum-Youn Gwak
Summary: The clinical implications of nonalcoholic fatty liver disease (NAFLD) in subjects who fulfill the diagnostic criteria of metabolic (dysfunction)-associated fatty liver disease (MAFLD) are unknown.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Amir M. Pirmoazen, Aman Khurana, Andreas M. Loening, Tie Liang, Vijay Shamdasani, Hua Xie, Ahmed El Kaffas, Aya Kamaya
Summary: In this study, we found that AC, Nakagami, SI, SS, MBF, and HRI have the best correlation with MRI-PDFF and show high diagnostic performance for detecting and classifying hepatic steatosis.
INVESTIGATIVE RADIOLOGY
(2022)